AVBP News
Companies Pushing Experimental Treatments Toward Their Biggest Tests
These biotechnology companies are advancing important developments. NeOnc Technologies Holdings (NASDAQ:NTHI) is outlining plans for a major international brain cancer trial, Azitra (NYSEAMERICAN:AZTR) is preparing human testing of its experimental anti-wrinkle technology, ArriVent BioPharma (NASDAQ:AVBP) is reporting encouraging early response data for its gastrointestinal cancer candidate, Xencor (NASDAQ:XNCR) is advancing its experimental kidney cancer therapy toward a potential registration-enabling study, and SciSparc (NASDAQ:SPRC) is moving closer to patient enrollment in its Phase IIb Tourette syndrome trial.
24-7 Market News
Companies Pushing Experimental Treatments Toward Their Biggest Tests
These biotechnology companies are advancing important developments. NeOnc Technologies Holdings (NASDAQ:NTHI) is outlining plans for a major international brain cancer trial, Azitra (NYSEAMERICAN:AZTR) is preparing human testing of its experimental anti-wrinkle technology, ArriVent BioPharma (NASDAQ:AVBP) is reporting encouraging early response data for its gastrointestinal cancer candidate, Xencor (NASDAQ:XNCR) is advancing its experimental kidney cancer therapy toward a potential registration-enabling study, and SciSparc (NASDAQ:SPRC) is moving closer to patient enrollment in its Phase IIb Tourette syndrome trial.
24-7 Market News
ARRIVENT BIOPHARMA AVBP INVESTORS: Contact Kirby McInerney LLP About the Firms Securities Investigation Following 47.3% Share Drop
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Arrivent BioPharma (Arrivent or the Company) (NASDAQ: AVBP) investors concerning the Companys and/or members of its senior managements possible violation of the federal securities laws or other unlawful business...
Business Wire
ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky
ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & KorsinskyPR NewswireNEW YORK, Oct. 13, 2026ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of lead...
PR Newswire
AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ArriVent BioPharma, Inc. (ArriVent or the Company) (NASDAQ: AVBP) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...
Business Wire
AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharmaPR NewswireNEW YORK, Oct. 7, 2026AVBP was down 56.7...
PR Newswire
ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP) ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)PR NewswireNEW YORK, Oct. 6...
PR Newswire
ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low
ArriVent BioPharma announced its Phase 3 lung cancer trial for firmonertinib missed the primary endpoint but showed secondary benefits.read more...
Benzinga
ArriVent BioPharma (NASDAQ:AVBP) Upgraded at Truist Financial
Truist Financial upgraded ArriVent BioPharma to a "strong-buy" rating in a research note on Monday...
MarketBeat
ArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on Monday
ArriVent BioPharma (NASDAQ:AVBP) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-arrivent-biopharma-inc-stock...
MarketBeat